Welcome to Burg Simpson Eldredge Hersh and Jardine's site, please upgrade your Flash Plugin and enable JavaScript.
Hot Topics
Janet Abaray Spearheads Class Action Suit Against Bengals
Explosion Accidents:
"Pooch alive after
Breck blast"
– Denver Post
"Baxter to Proceed with Recall of Remaining Heparin Sodium Vial Products"
– FDA
Yamaha Rhino ATV Rollover Accidents
and Injuries
"UBS Hit by
Another Lawsuit"
– Ben Levinsohn, BusinessWeek
"Hedge Funds
Frozen Shut"
– Matthew Goldstein, BusinessWeek
"MRI Contrast Can Cause Disease – Gadolinium Blamed
For Problems"
– Dayle Cedars
7News, Denver, CO
Results
$690,000,000
Global settlement with Eli Lilly and Company regarding its product Zyprexa negotiated by a plaintiffs' attorney group including members of Burg Simpson.
$5,800,000
Hines, et al, vs. Cody Gas Company, et al: verdict for injuries, damages, losses from gas explosion.
CLICK HERE FOR MORE INFORMATION
Our Offices
40 Inverness Drive East
Denver, CO 80112
Phone: 303.792.5595
Fax: 303.708.0527
WYOMING OFFICE
Phone: 307.527.7891
Fax: 307.527.7897
OHIO OFFICE
Phone: 513.852.5600
Fax: 513.852.5611
DALLAS OFFICE
Phone: 972.934.1313
Fax: 972.231.3983
ARIZONA OFFICE
Phone: 602.508.6040
Litigation Updates
Ketek Associated With Severe Liver Damage & Death
We'd like to alert you to recent developments concerning Ketek, a popular antibiotic marketed by Sanofi-Aventis SA. Ketek has been associated with severe liver damage and death. In April 2004, Ketek was approved for upper respiratory infections in patients 18 years and older. The FDA had rejected the drug in 2001 and 2003, asking for more safety information. Despite Sanofi's flawed and unreliable clinical studies, the FDA relied on the drug's safety record in Europe and Japan to approve the drug for sale in the United States. The Senate Finance Committee is now conducting an investigation into the FDA's approval, and Sen. Charles Grassley, Chairman, told the Wall Street Journal, "The Ketek allegations appear to be as serious as anything I've seen so far." On June 29, 2006, the FDA issued a safety alert concerning Ketek's association with serious liver injury, liver failure and 4 reported deaths, and announced new safety information to be added to Ketek's label.
In light of concerns that Ketek may be up to four times more toxic than other antibiotics, the FDA called for the halt of a clinical trial of Ketek in nearly 4,000 infants and children, in which it was being studied for ear infections and tonsillitis, in spite of its having caused liver failure, blurred vision, and loss of consciousness in adults. One of the lead investigators of a key clinical trial is now in federal prison after pleading guilty to fraud charges.
FDA had previously published a January 20, 2006 Safety Information Alert, citing liver problems, including three cases of serious liver toxicity (one recovered, one had a liver transplant, one died). All three patients had previously been healthy.
More than 5 million prescriptions have been written in the U.S. since Ketek's approval on 4/1/04. According to IMS Health, 3.5 million prescriptions were written in the U.S. in 2005, with sales of $193 million.
If you are interested in a co-counsel relationship with Burg Simpson on Ketek cases you acquire, please contact Seth Katz or Kerry Jardine
